Save the Date: Profound Medical to Host Investor Event at AUA 2025

Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing customizable, incision-free therapies for the ablation of diseased tissue [3][4] - The company is known for its TULSA-PRO® technology, which combines real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control for treating prostate diseases [4] Upcoming Investor Event - Profound will host a hybrid investor event on April 28, 2025, during the American Urological Association's Annual Meeting in Las Vegas, NV [1] - The event will feature presentations from the management team and leading physicians discussing TULSA-PRO®, peri-operative results from the Level 1 CAPTAIN post-market study, the upcoming TULSA-AI® module for BPH, and the TULSA+ program [2] TULSA-PRO® Technology - TULSA-PRO® is designed to treat a wide range of prostate diseases, including low-, intermediate-, and high-risk prostate cancer, as well as benign prostatic hyperplasia (BPH) [4] - The procedure is incision- and radiation-free, performed in a single session, and aims to preserve urinary continence and sexual function while effectively targeting prostate tissue [4] Sonalleve® Technology - Profound is also commercializing Sonalleve®, a therapeutic platform approved for treating uterine fibroids and palliative pain from bone metastases [5] - The technology has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments, with ongoing exploration for additional markets [5]